Method of Adjuvant Cancer Treatment

Abstract

The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of debrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).

What is claimed is: 
     
         1 . A method of providing adjuvant treatment to a patient with a prior diagnosis of melanoma which has been resected, comprising the step of administering to such a patient therapeutically effective doses of dabrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS). 
     
     
         2 . The method of  claim 1 , wherein dabrafenib is administered at an amount of 150 mg twice a day. 
     
     
         3 . The method of  claim 1 , wherein trametinib is administered at an amount of 2 mg once daily. 
     
     
         4 . The method of  claim 1 , wherein the patient has a prior diagnosis of stage III melanoma which been resected. 
     
     
         5 . The method of  claim 1 , wherein the patient has a prior diagnosis of BRAF V600 mutation-positive melanoma which has been resected. 
     
     
         6 . A method of increasing relapse-free survival (RFS) of a patient after resection of melanoma, comprising the administration of a) dabrafenib and b) trametinib. 
     
     
         7 . The method of  claim 6 , wherein the melanoma is BRAF V600 mutation-positive. 
     
     
         8 . A composition comprising the combination of dabrafenib and trametinib for use in increasing relapse-free survival (RFS) in a patient after resection of melanoma.